

# Paul P Tak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4086972/publications.pdf>

Version: 2024-02-01

93  
papers

16,675  
citations

81434

41  
h-index

60403

85  
g-index

95  
all docs

95  
docs citations

95  
times ranked

18462  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. <i>Biomedicines</i> , 2022, 10, 324.	1.4	4
2	Increased Frequency of CD4+ Follicular Helper T and CD8+ Follicular T Cells in Human Lymph Node Biopsies during the Earliest Stages of Rheumatoid Arthritis. <i>Cells</i> , 2022, 11, 1104.	1.8	13
3	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <sc>Pharmacogenomics-Driven</sc> Machine Learning Approach. <i>Arthritis Care and Research</i> , 2022, 74, 879-888.	1.5	15
4	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	1.0	16
5	Promotion of macrophage activation by Tie2 in the context of the inflamed synovia of rheumatoid arthritis and psoriatic arthritis patients. <i>Rheumatology</i> , 2020, 59, 426-438.	0.9	19
6	Human Lymph Node Stromal Cells Have the Machinery to Regulate Peripheral Tolerance during Health and Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5713.	1.8	5
7	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.5	43
8	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	1.0	3
9	Molecular Characterization of Human Lymph Node Stromal Cells During the Earliest Phases of Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 1863.	2.2	17
10	Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1339-1345.	0.5	26
11	Therapeutic options for targeting inflammatory osteoarthritis pain. <i>Nature Reviews Rheumatology</i> , 2019, 15, 355-363.	3.5	227
12	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
13	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 967-975.	1.6	46
14	Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 179-185.	0.5	163
15	Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes. <i>Rheumatology</i> , 2018, 57, 909-920.	0.9	21
16	Distinctive expression of T cell guiding molecules in human autoimmune lymph node stromal cells upon TLR3 triggering. <i>Scientific Reports</i> , 2018, 8, 1736.	1.6	20
17	Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 35.	1.6	29
18	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 528-538.	0.9	42

#	ARTICLE	IF	CITATIONS
19	Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 277-285.	0.5	118
20	Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1924-1930.	0.5	50
21	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
22	Synovial IL-21/TNF-producing CD4+ T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. <i>Journal of Leukocyte Biology</i> , 2017, 101, 775-783.	1.5	33
23	Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 70-76.	2.9	57
24	Rheumatoid Arthritis and Other Inflammatory Articular Diseases. , 2017, , 1105-1140.		1
25	Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis. <i>PLoS ONE</i> , 2017, 12, e0182751.	1.1	43
26	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 170-177.	0.5	48
27	Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8284-8289.	3.3	742
28	Intracellular delivery of poly(I:C) induces apoptosis of fibroblast-like synoviocytes via an unknown dsRNA sensor. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 343-349.	1.0	2
29	Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis. <i>European Journal of Immunology</i> , 2016, 46, 2812-2821.	1.6	31
30	Human lymph-node CD8+ T cells display an altered phenotype during systemic autoimmunity. <i>Clinical and Translational Immunology</i> , 2016, 5, e67.	1.7	23
31	Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 75.	1.6	85
32	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Pharmacokinetic Modeling: Initial Experience in Patients With Early Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 587-596.	2.9	19
33	Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synovocyte activation by suppressing HDAC5 expression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 430-438.	0.5	68
34	The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 422-429.	0.5	134
35	Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. <i>Rheumatology</i> , 2016, 55, 607-614.	0.9	65
36	Smelling the Diagnosis: The Electronic Nose as Diagnostic Tool in Inflammatory Arthritis. A Case-Reference Study. <i>PLoS ONE</i> , 2016, 11, e0151715.	1.1	27

#	ARTICLE	IF	CITATIONS
37	Prevalence of Anti-â€œCitruinated Protein Antibodies and IgM Rheumatoid Factor in First-â€œDegree Relatives of Dutch Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 3324-3326.	2.9	3
38	DNA Methylome Signature in Synoviocytes From Patients With Early Rheumatoid Arthritis Compared to Synoviocytes From Patients With Longstanding Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1978-1980.	2.9	74
39	Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman-â€™s Disease. <i>Frontiers in Immunology</i> , 2015, 6, 625.	2.2	11
40	JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1763-1771.	0.5	46
41	CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 6.	1.6	19
42	Nuclear Factor-â€™B-â€œinducing Kinase Is Expressed in Synovial Endothelial Cells in Patients with Early Arthritis and Correlates with Markers of Inflammation: A Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1573-1581.	1.0	20
43	Summary of Sensitivity and Specificity for Psoriatic Arthritis in a South African Cohort according to Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 960-962.	1.0	3
44	14-3-3-â€™ Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1587-1594.	1.0	28
45	Tertiary Lymphoid Structures in Rheumatoid Arthritis. <i>American Journal of Pathology</i> , 2015, 185, 1935-1943.	1.9	34
46	Histological characteristics of ligament healing after bio-enhanced repair of the transected goat ACL. <i>Journal of Experimental Orthopaedics</i> , 2015, 2, 4.	0.8	12
47	Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2443-2450.	1.1	12
48	Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2097-2099.	0.5	3
49	Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1603-1611.	0.5	35
50	MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 499-505.	0.5	130
51	FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2216-2223.	0.5	9
52	MOR103, a human monoclonal antibody to granulocyte-â€™macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1058-1064.	0.5	133
53	Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model. <i>PLoS ONE</i> , 2015, 10, e0122836.	1.1	6
54	Somatic Variation of T-Cell Receptor Genes Strongly Associate with HLA Class Restriction. <i>PLoS ONE</i> , 2015, 10, e0140815.	1.1	30

#	ARTICLE	IF	CITATIONS
55	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	1.1	34
56	Tie2 Signaling Cooperates with TNF to Promote the Pro-Inflammatory Activation of Human Macrophages Independently of Macrophage Functional Phenotype. PLoS ONE, 2014, 9, e82088.	1.1	44
57	Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program. PLoS ONE, 2014, 9, e87379.	1.1	71
58	Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Ameliorates Disease in Rat Collagen-Induced Arthritis. PLoS ONE, 2014, 9, e104530.	1.1	157
59	Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1654-1658.	0.5	150
60	Local Synovial Engagement of Angiogenic TIE2 Is Associated With the Development of Persistent Erosive Rheumatoid Arthritis in Patients With Early Arthritis. Arthritis and Rheumatism, 2013, 65, 3073-3083.	6.7	20
61	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of the Rheumatic Diseases, 2013, 72, 329-336.	0.5	158
62	Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Annals of the Rheumatic Diseases, 2013, 72, 337-344.	0.5	74
63	A5.31...The Role of BOB1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity. Annals of the Rheumatic Diseases, 2013, 72, A41.3-A42.	0.5	0
64	A2.15...Relative Overexpression of Transmembrane Versus Soluble TNF in Human and Experimental Spondyloarthritis. Annals of the Rheumatic Diseases, 2013, 72, A9.3-A10.	0.5	5
65	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	0.5	354
66	Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Annals of the Rheumatic Diseases, 2012, 71, 1911-1912.	0.5	45
67	Stimulation of the cytosolic dsRNA sensor MDA-5 induces cell death in fibroblast-like synoviocytes. Annals of the Rheumatic Diseases, 2012, 71, A77.3-A78.	0.5	0
68	A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. Dermatology, 2012, 225, 298-303.	0.9	13
69	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Annals of the Rheumatic Diseases, 2011, 70, 423-427.	0.5	101
70	B cell receptor repertoire analysis in clinically involved and uninvolved skin of systemic sclerosis patients treated with CD20 depletion therapy: baseline and follow-up. Annals of the Rheumatic Diseases, 2011, 70, A62-A63.	0.5	0
71	Local downregulation of pre-B cell colony-enhancing factor/visfatin using an adeno-associated virus type 5 vector encoding a specific small hairpin RNA for PBEF results in amelioration of arthritis. Annals of the Rheumatic Diseases, 2011, 70, A77-A77.	0.5	0
72	Editorial - Lessons Learned from Synovial Tissue Analysis. Open Rheumatology Journal, 2011, 5, 98-99.	0.1	0

#	ARTICLE	IF	CITATIONS
73	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
74	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
75	Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. <i>Arthritis and Rheumatism</i> , 2008, 58, 1582-1589.	6.7	114
76	Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2006, 31, 109-116.	0.6	77
77	Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?. <i>Journal of rheumatology Supplement, The</i> , 2005, 72, 25-6.	2.2	12
78	Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. <i>Arthritis and Rheumatism</i> , 2002, 46, 2034-2038.	6.7	262
79	Inhibitor of nuclear factor $\kappa$ B kinase $\lambda$ is a key regulator of synovial inflammation. <i>Arthritis and Rheumatism</i> , 2001, 44, 1897-1907.	6.7	236
80	The effects of interferon- $\gamma$ treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 270.	6.7	84
81	Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. <i>Arthritis and Rheumatism</i> , 2000, 43, 593.	6.7	263
82	Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patients. <i>Arthritis and Rheumatism</i> , 2000, 43, 1488-1495.	6.7	106
83	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. <i>Arthritis and Rheumatism</i> , 2000, 43, 1820-1830.	6.7	161
84	Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. <i>Arthritis and Rheumatism</i> , 2000, 43, 2160-2168.	6.7	79
85	The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. <i>Arthritis and Rheumatism</i> , 2000, 43, 2619-2633.	6.7	353
86	Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. <i>Arthritis and Rheumatism</i> , 1999, 42, 650-658.	6.7	125
87	Detection of <i>Borrelia burgdorferi sensu stricto</i> by reverse line blot in the joints of Dutch patients with Lyme arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1473-1480.	6.7	35
88	Detection of bacterial DNA in serial synovial samples obtained during antibiotic treatment from patients with septic arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2198-2203.	6.7	87
89	Poor Expression of T Cell-Derived Cytokines and Activation and Proliferation Markers in Early Rheumatoid Synovial Tissue. <i>Clinical Immunology and Immunopathology</i> , 1998, 88, 84-90.	2.1	47
90	Asymptomatic synovitis precedes clinically manifest arthritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 1481-1488.	6.7	275

#	ARTICLE	IF	CITATIONS
91	Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. , 1998, 186, 75-81.		107
92	Reduction of synovial inflammation after anti-cd4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 1457-1465.	6.7	185
93	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. , 0, .		1